PuriBlood Medical Co.,Ltd.

As of June 30, 2026, PuriBlood Medical Co.,Ltd. carries a market capitalization of 1.15B, placing it among publicly traded companies globally. Its enterprise value stands at 1.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, PuriBlood Medical Co.,Ltd. has 14.35M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, PuriBlood Medical Co.,Ltd. maintains a current ratio of 1.70, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, PuriBlood Medical Co.,Ltd.'s stock has declined approximately 8.38% over the past 52 weeks. The 50-day moving average sits at 74.09, while the 200-day moving average is 71.38.

As of June 30, 2026, PuriBlood Medical Co.,Ltd. holds 39.78M in cash and equivalents against 47.46M in total debt, resulting in a net debt position of -11.37M. Total book value stands at 109.39M, with working capital of 42.90M providing operational flexibility.

PuriBlood Medical Co.,Ltd.'s most recent stock split took place on August 17, 2026 with a 917:925 split ratio.